[ad_1]
What happened
Biotechnology actions at the clinical stage Five Prime Therapeutics (NASDAQ: FPRX) are up 364% on the pre-stock market Wednesday morning. Biotechnology stock is erupting in response to positive results from mid-term trials of the stomach cancer drug candidate, bemarituzumab.
Specifically, Five Prime and partner Zai Laboratory (NASDAQ: ZLAB) reported that the combination of bémarituzumab and mFOLFOX6 chemotherapy beat placebo plus mFOLFOX6 on three efficacy endpoints – median progression-free survival, median overall survival and overall response rate – in patients with a factor 2b receptor. fibroblast growth positive, HER2 negative advanced first-line cancer of the gastric or gastroesophageal junction. Zai Lab owns the development and commercial rights for the drug in China through a licensing agreement with Five Prime.
Image source: Getty Images.
So what
Bemarituzumab will likely still have to pass testing at a larger pivot stage to gain approval in China or the United States. But a first-line drug for stomach cancer undoubtedly has enormous commercial potential. Stomach cancer, after all, is one of the most common types of malignant tumors, as well as one of the leading causes of death worldwide. Against this backdrop, it’s no surprise that investors are jumping into this small-cap biotech stock this morning.
Now what
Five Prime and Zai Lab, according to yesterday’s press release, also noted that bemarituzumab may have anticancer activity on a range of solid tumors, such as non-small squamous cell lung cancer, triple breast cancer. negative, ovarian cancer, pancreatic cancer and intrahepatic cholangiocarcinoma.
This means that bemarituzumab could turn out to be a franchise-level cancer drug. Since these rare gems rarely go unnoticed by large pharmaceutical companies, Five Prime is likely to rise to the top of the buyout rumor soon. Stay tuned.
[ad_2]
Source link